Investigational drug · Phase 2
GTX-102
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Angelman Syndrome.
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
5
Any phase or sponsor naming "GTX-102"
First trial start
2020
Feb 24, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GTX-102", any sponsor or status.
Conditions studied
As listed on its trial records.
- Angelman Syndrome
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "GTX-102" as an intervention, largest first.
- Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)Pivotal-lookingTerminated
Ultragenyx Pharmaceutical IncIndustry
NCT06617429 · 129 participants · Start Dec 3, 2024 · Primary completion Jul 10, 2026
Drug: GTX-102 · For: Angelman Syndrome
Sites: Los Angeles, California; San Diego, California; San Francisco, California · 28 sites in all
Ultragenyx Pharmaceutical IncIndustry
NCT04259281 · 74 participants · Start Feb 24, 2020 · Primary completion Jan 8, 2025
Drug: GTX-102 · For: Angelman Syndrome
Sites: Los Angeles, California; San Diego, California; Atlanta, Georgia · 25 sites in all
- Long-term Extension of GTX-102 in Angelman SyndromePivotal-lookingTerminated
Ultragenyx Pharmaceutical IncIndustry
NCT06415344 · 66 participants · Start Jul 31, 2024 · Primary completion Oct 30, 2026
Drug: GTX-102 · For: Angelman Syndrome
Sites: Los Angeles, California; San Diego, California; Atlanta, Georgia · 23 sites in all
Ultragenyx Pharmaceutical IncIndustry
NCT07157254 · 55 participants · Start Oct 13, 2025 · Primary completion Oct 30, 2026
Drug: GTX-102 · For: Angelman Syndrome
Sites: Los Angeles, California; Chicago, Illinois; Baltimore, Maryland · 21 sites in all
- Comparative Bioavailability of Betamethasone Oral Solution Metered Spray (GTX-102) in Healthy SubjectsStatus unknown
Grace Therapeutics Inc.Industry
NCT05531890 · 48 participants · Start Sep 13, 2022 · Primary completion Nov 24, 2022
Drug: GTX-102 medium dose fast Period 1 and Period 2; GTX-102 medium dose slow Period 1 and Period 2 and 4 more · For: Ataxia Telangiectasia
Sites: Toronto, Canada
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Angelman Syndrome
- obudanersenION582Phase 33 trials
Ionis Pharmaceuticals · Angelman Syndrome
- rugonersenPhase 31 trial
OHB Pediatrics Ltd. · Angelman Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.